Compass Therapeutics Stock Market Outlook
| CMPX Stock | USD 6.22 0.11 1.74% |
Slightly above 50% of Compass Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Compass Therapeutics suggests that some traders are interested. Compass Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Compass Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 50
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Compass Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Compass Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Compass Therapeutics is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Compass Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Compass Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Compass Therapeutics Advice
The Compass recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Compass Therapeutics. Macroaxis does not own or have any residual interests in Compass Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Compass Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Compass Therapeutics has a Risk Adjusted Performance of 0.178, Jensen Alpha of 0.8332, Total Risk Alpha of 0.5869, Sortino Ratio of 0.2411 and Treynor Ratio of 1.33We provide trade advice to complement the prevailing expert consensus on Compass Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Compass Therapeutics is not overpriced, please confirm all Compass Therapeutics fundamentals, including its current ratio, and the relationship between the ebitda and number of employees . Given that Compass Therapeutics has a price to book of 5.45 X, we suggest you to validate Compass Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Compass Therapeutics Trading Alerts and Improvement Suggestions
| Compass Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 850 K. Net Loss for the year was (49.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Blanger Celebrates 60 Years of Design Excellence |
Compass Therapeutics Returns Distribution Density
The distribution of Compass Therapeutics' historical returns is an attempt to chart the uncertainty of Compass Therapeutics' future price movements. The chart of the probability distribution of Compass Therapeutics daily returns describes the distribution of returns around its average expected value. We use Compass Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Compass Therapeutics returns is essential to provide solid investment analysis for Compass Therapeutics.
| Mean Return | 0.88 | Value At Risk | -5.14 | Potential Upside | 7.61 | Standard Deviation | 3.80 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Compass Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Compass Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Compass Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Compass Therapeutics back and forth among themselves.
| Shares | Fmr Inc | 2025-06-30 | 4.1 M | Blue Owl Capital Holdings Lp | 2025-06-30 | 2.6 M | Geode Capital Management, Llc | 2025-06-30 | 2.3 M | Jpmorgan Chase & Co | 2025-06-30 | 2.1 M | State Street Corp | 2025-06-30 | 2 M | Silverarc Capital Management, Llc | 2025-06-30 | 1.2 M | Millennium Management Llc | 2025-06-30 | 851.2 K | Northern Trust Corp | 2025-06-30 | 734.7 K | Caption Management, Llc | 2025-06-30 | 725.5 K | Orbimed Advisors, Llc | 2025-06-30 | 15.2 M | Tang Capital Management Llc | 2025-06-30 | 13.5 M |
Compass Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (1.8M) | (151.2M) | 27.0M | 46.8M | 53.8M | 56.5M | |
| Change In Cash | 97.2M | (109.6M) | (10.7M) | 19.3M | 17.3M | 18.2M | |
| Free Cash Flow | (21.2M) | (34.3M) | (40.6M) | (44.9M) | (40.4M) | (42.4M) | |
| Depreciation | 1.6M | 1.9M | 1.9M | 1.8M | 1.6M | 1.6M | |
| Other Non Cash Items | 41K | (871K) | 6.0M | (1.7M) | (1.9M) | (1.8M) | |
| Capital Expenditures | 1.6M | 212K | 30K | 44K | 39.6K | 37.6K | |
| Net Income | (82.2M) | (39.2M) | (42.5M) | (49.4M) | (44.4M) | (46.7M) | |
| End Period Cash Flow | 144.5M | 34.9M | 24.2M | 43.5M | 39.1M | 43.2M | |
| Change To Netincome | 1.1M | 4.9M | 54.6M | 5.3M | 6.0M | 5.7M |
Compass Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Compass Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Compass Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Compass stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.83 | |
β | Beta against Dow Jones | 0.65 | |
σ | Overall volatility | 3.91 | |
Ir | Information ratio | 0.21 |
Compass Therapeutics Volatility Alert
Compass Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Compass Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Compass Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Compass Therapeutics Fundamentals Vs Peers
Comparing Compass Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Compass Therapeutics' direct or indirect competition across all of the common fundamentals between Compass Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Compass Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Compass Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Compass Therapeutics to competition |
| Fundamentals | Compass Therapeutics | Peer Average |
| Return On Equity | -0.38 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Current Valuation | 951.41 M | 16.62 B |
| Shares Outstanding | 177.86 M | 571.82 M |
| Shares Owned By Insiders | 11.18 % | 10.09 % |
| Shares Owned By Institutions | 84.39 % | 39.21 % |
| Number Of Shares Shorted | 22.99 M | 4.71 M |
| Price To Book | 5.45 X | 9.51 X |
| Price To Sales | 439.25 X | 11.42 X |
| Revenue | 850 K | 9.43 B |
| EBITDA | (54.87 M) | 3.9 B |
| Net Income | (49.38 M) | 570.98 M |
| Cash And Equivalents | 132.02 M | 2.7 B |
| Cash Per Share | 1.31 X | 5.01 X |
| Total Debt | 6.63 M | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 12.36 X | 2.16 X |
| Book Value Per Share | 1.18 X | 1.93 K |
| Cash Flow From Operations | (44.85 M) | 971.22 M |
| Short Ratio | 9.44 X | 4.00 X |
| Earnings Per Share | (0.45) X | 3.12 X |
| Target Price | 13.23 | |
| Number Of Employees | 35 | 18.84 K |
| Beta | 1.27 | -0.15 |
| Market Capitalization | 1.14 B | 19.03 B |
| Total Asset | 140.4 M | 29.47 B |
| Retained Earnings | (364.68 M) | 9.33 B |
| Working Capital | 123.88 M | 1.48 B |
| Net Asset | 140.4 M |
Note: Disposition of 46777 shares by Schuetz Thomas J. of Compass Therapeutics at 5.35 subject to Rule 16b-3 [view details]
Compass Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Compass . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 6.22 | |||
| Day Typical Price | 6.22 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.11) |
Compass Therapeutics Target Price Consensus
Compass target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Compass Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most Compass analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Compass stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Compass Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCompass Therapeutics Target Price Projection
Compass Therapeutics' current and average target prices are 6.22 and 13.23, respectively. The current price of Compass Therapeutics is the price at which Compass Therapeutics is currently trading. On the other hand, Compass Therapeutics' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Compass Therapeutics Market Quote on 5th of February 2026
Target Price
Analyst Consensus On Compass Therapeutics Target Price
Compass Therapeutics Analyst Ratings
Compass Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Compass Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Compass Therapeutics' financials, market performance, and future outlook by experienced professionals. Compass Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Compass Therapeutics Buy or Sell Advice
When is the right time to buy or sell Compass Therapeutics? Buying financial instruments such as Compass Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Compass Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.